tiprankstipranks
Trending News
More News >
Orexo AB (SE:ORX)
:ORX
Advertisement

Orexo AB (ORX) Price & Analysis

Compare
1 Followers

ORX Stock Chart & Stats


Orexo AB News

ORX FAQ

What was Orexo AB’s price range in the past 12 months?
Orexo AB lowest stock price was kr9.18 and its highest was kr30.50 in the past 12 months.
    What is Orexo AB’s market cap?
    Orexo AB’s market cap is $975.69M.
      When is Orexo AB’s upcoming earnings report date?
      Orexo AB’s upcoming earnings report date is Oct 23, 2025 which is in 23 days.
        How were Orexo AB’s earnings last quarter?
        Orexo AB released its earnings results on Jul 16, 2025. The company reported -kr1.2 earnings per share for the quarter, missing the consensus estimate of -kr0.37 by -kr0.83.
          Is Orexo AB overvalued?
          According to Wall Street analysts Orexo AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Orexo AB pay dividends?
            Orexo AB does not currently pay dividends.
            What is Orexo AB’s EPS estimate?
            Orexo AB’s EPS estimate is -0.5.
              How many shares outstanding does Orexo AB have?
              Orexo AB has 34,710,640 shares outstanding.
                What happened to Orexo AB’s price movement after its last earnings report?
                Orexo AB reported an EPS of -kr1.2 in its last earnings report, missing expectations of -kr0.37. Following the earnings report the stock price went down -6.173%.
                  Which hedge fund is a major shareholder of Orexo AB?
                  Currently, no hedge funds are holding shares in SE:ORX

                  Company Description

                  Orexo AB

                  Orexo AB (ORX) is a pharmaceutical company based in Sweden, specializing in the development and commercialization of innovative treatments for opioid dependence and other mental health disorders. The company operates primarily in the pharmaceutical sector, focusing on providing effective solutions for patients with unmet medical needs. Orexo's core products include Zubsolv, a medication for the treatment of opioid dependence, and other proprietary products aimed at improving patient adherence and outcomes in mental health.

                  Orexo AB (ORX) Earnings & Revenues

                  ORX Company Deck

                  ORX Earnings Call

                  Q2 2025
                  0:00 / 0:00
                  Earnings Call Sentiment|Neutral
                  The earnings call presented a mixed view with notable achievements in ZUBSOLV demand stabilization in the Commercial segment and promising developments in the AmorphOX platform. However, these were offset by challenges such as the decline in ZUBSOLV revenues, delays in OX124 approval, and increased legal costs, which impacted financial performance and raised liquidity concerns.View all SE:ORX earnings summaries
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  AlzeCure Pharma AB
                  Klaria Pharma Holding AB
                  Nanexa AB
                  Enzymatica AB
                  Enorama Pharma AB
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis